FDAnews
www.fdanews.com/articles/113483-biogeneric-approval-pathway-could-save-billions-cbo-says

Biogeneric Approval Pathway Could Save Billions, CBO Says

January 6, 2009
Government healthcare plans such as Medicare and Medicaid could save more than $10 billion over about a decade under a modified approval pathway for follow-on biologics (FOBs), according to a Congressional Budget Office (CBO) report. The CBO estimates that if Congress established a pathway to approve FOBs, allowing innovators to have about 12 years of exclusivity, the increased competition would put downward pressure on prices.
Washington Drug Letter